Salarius Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Salarius Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-71.1%

Buyback Yield

Total Shareholder Yield	-71.1%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SLRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLRX's dividend payments have been increasing.

Dividend Yield vs Market

Salarius Pharmaceuticals Dividend Yield vs Market

How does SLRX dividend yield compare to the market?
Segment	Dividend Yield
Company (SLRX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.4%
Industry Average (Biotechs)	2.4%
Analyst forecast (SLRX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate SLRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SLRX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLRX has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 14:05
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aydin Huseynov	Benchmark Company
Michael King	H.C. Wainwright & Co.

Salarius Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Salarius Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from C/M Capital Master Fund, LP

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Salarius adds 12% after updates on clinical programs and financials

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

Price target decreased to US$4.10

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

New 90-day high: US$1.58

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

New 90-day high: US$1.35

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Salarius Pharma raises $3.5M via warrant exercise

New 90-day high: US$1.08

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.096 loss per share

Salarius Pharmaceuticals EPS in-line, beats on revenue

New 90-day low: US$0.73

New 90-day low: US$0.80

New 90-day low - US$0.99

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.